Abstract

​

Scientific advances and expanding market potential of biotechnology has led to growing interest in biosimilars. In China, biosimilars also benefit from, an influx of Chinese experts returning from overseas, strong financial support in the form of Venture Capital and supportive national polices.

Statistics of IMS predicts that as more and more drug patents are going to expire, biosimilar will occupy 20% of the global pharmaceutical market in the following five years. According to Thomson Reuters, currently the number of R&D projects of China ranks highest worldwide, while in terms of the number of core patents, China is positioned third after the USA and EU. Currently, tumors, diabetes and the immune system form the main focus areas for Chinese biosimilar development. ​